Immunic is a biotechnology company developing orally available therapies for the treatment of chronic inflammatory and autoimmune diseases. Three small molecule products are under development:
Vidofludimus Calcium (IMU-838) is a selective immunomodulator that activates the transcription factor Nurr1, which is associated with direct neuroprotective properties. In addition, Vidofludimus Calcium inhibits the protein DHODH, a key enzyme in the metabolism of overactive immune cells and virus-infected cells, which is associated with its anti-inflammatory and antiviral effects. Vidofludimus Calcium is currently in two parallel Phase 3 trials for the treatment of relapsing multiple sclerosis. In addition, a phase 2 trial in progressive multiple sclerosis is underway. Vidofludimus Calcium has the potential to demonstrate medically important advantages over currently approved MS treatments due to its combined anti-inflammatory, antiviral and neuroprotective properties, as well as its favourable safety and tolerability profile.
IMU-856 is an orally available, systemic-acting, highly selective, and potent modulator of SIRT6, a protein that acts as a transcriptional regulator of intestinal barrier function and intestinal epithelial regeneration. Following very promising phase 1b data in patients with celiac disease, preparations for a corresponding phase 2 study are now underway. IMU-856 could represent a unique treatment approach for patients with gastrointestinal disorders, as the mechanism of action targets the regeneration of intestinal wall architecture and the restoration of intestinal barrier function while maintaining full immune competence.
IMU-381, currently in preclinical development, is a next-generation molecule specifically designed to meet the needs of gastrointestinal diseases.
Immunic, Inc. has its headquarters in New York City, USA and trades on the NASDAQ technology exchange under the symbol "IMUX". The research and development activities are managed from Gräfelfing in Germany.
